Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Yellow Fever01:18

Yellow Fever

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...
Cross-reactivity00:42

Cross-reactivity

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccinations01:51

Vaccinations

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nine-valent human papillomavirus vaccine: implications for cervical elimination.

The Lancet. Infectious diseases·2026
Same author

SPIRIT 2025 statement: updated guideline for protocols of randomised trials.

Lancet (London, England)·2026
Same author

Nor-ursodeoxycholic Acid for Metabolic Dysfunction-associated Steatotic Liver Disease: Is There Enough Evidence for Clinical Use? A Critique of a Phase III Trial and Regulatory Endorsement of the Drug.

Journal of clinical and experimental hepatology·2026
Same author

Economic evaluation of combination vaccines: Enabling a more comprehensive assessment of their benefits and challenges.

Vaccine·2026
Same author

Association of butter and plant-based oils with mortality: Further clarifying the butter.

The National medical journal of India·2026
Same author

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Vaccine·2026
Same journal

APASL clinical practice guidance: the diagnosis and management of patients with Wilson's disease.

Hepatology international·2026
Same journal

Pathological transcriptional retention of Cyp26b1 in perirenal adipose-derived stem cells contributes to MASLD progression.

Hepatology international·2026
Same journal

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international·2026
Same journal

Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma.

Hepatology international·2026
Same journal

Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.

Hepatology international·2026
Same journal

Spatial analysis identifies LAMTOR2 overexpression in hepatocellular carcinoma with vessels encapsulating tumor clusters.

Hepatology international·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Hepatitis E vaccine.

Rakesh Aggarwal1, Shahid Jameel

  • 1Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Rae Bareilly Road, Lucknow, 226 014, India.

Hepatology International
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Hepatitis E virus (HEV) infection is a growing global health concern. This review covers progress in developing new recombinant subunit vaccines for Hepatitis E, as traditional vaccines are not feasible.

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Related Experiment Videos

Last Updated: Jun 21, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Area of Science:

  • * Hepatology and Virology
  • * Vaccine Development and Immunology

Background:

  • * Hepatitis E is a significant emerging infectious disease, particularly in resource-limited areas, affecting approximately 2 billion people globally.
  • * The difficulty in culturing the Hepatitis E virus hinders the development of conventional live-attenuated or inactivated vaccines.
  • * Hepatitis E virus (HEV) poses a substantial public health burden, especially in endemic regions.

Purpose of the Study:

  • * To review the advancements in developing recombinant subunit vaccines for Hepatitis E.
  • * To summarize the current state of vaccine candidates based on the Hepatitis E virus capsid protein.
  • * To highlight the potential of novel vaccine strategies in combating Hepatitis E.

Main Methods:

  • * Review of scientific literature on Hepatitis E virus (HEV) research.
  • * Analysis of studies focusing on recombinant protein expression and vaccine formulation.
  • * Evaluation of preclinical and clinical trial data for HEV subunit vaccines.

Main Results:

  • * Significant progress has been achieved in creating subunit vaccines using the HEV capsid protein.
  • * Recombinant vaccine candidates have shown promising immunogenicity and efficacy in preliminary studies.
  • * The development of non-replicating, subunit-based vaccines offers a viable alternative for Hepatitis E prevention.

Conclusions:

  • * Recombinant subunit vaccines represent a promising approach to control Hepatitis E, overcoming limitations of traditional vaccine types.
  • * Further research and clinical trials are essential to establish the safety and effectiveness of these novel Hepatitis E vaccines.
  • * Successful development of these vaccines could significantly reduce the global burden of Hepatitis E infection.